Dyne Therapeutics’ (DYN) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $50.00 price objective on the stock.

A number of other research analysts have also issued reports on DYN. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target on the stock. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Scotiabank started coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. Finally, Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $12.31 on Monday. Dyne Therapeutics has a one year low of $11.18 and a one year high of $47.45. The company has a 50-day simple moving average of $14.33 and a 200-day simple moving average of $24.90. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -3.46 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 6,237 shares of company stock valued at $77,760 over the last quarter. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DYN. GF Fund Management CO. LTD. purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $50,000. Neo Ivy Capital Management purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Dyne Therapeutics by 6.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock valued at $3,378,000 after buying an additional 9,029 shares during the period. Voloridge Investment Management LLC purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $2,804,000. Finally, Two Sigma Advisers LP lifted its stake in shares of Dyne Therapeutics by 25.4% during the fourth quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock valued at $1,793,000 after buying an additional 15,400 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.